πŸ‡ΊπŸ‡Έ

US SEC Filing Intelligence

Β· daily

Mega Contracts Monitor ($100M+) β€” March 11, 2026

DHS dominates with $1.34B in mega contracts (82% of total value) focused on border barriers, walls, Coast Guard piers, and ICE detention facilities, signaling accelerated U.S. border/security infrastructure spend amid policy continuity. Construction firms (NAICS 236220) capture 85% of value via firm-fixed-price awards, offering multi-year revenue visibility despite execution risks. Diversification limited to IT/cloud ($160M Commerce) and space R&D ($131M NASA neutral), with 5/6 bullish signals underscoring sector tailwinds.

6 total filings
Β· daily

High-Value Federal Grants ($5M+) β€” March 11, 2026

DHS dominates with 4/6 contracts totaling ~$1.34B (82% of $1.63B aggregate), fueling bullish signals for border security construction via firm fixed price awards to non-small firms like Fisher Sand & Gravel ($596M) and Granite ($512M). Multi-year performance periods (up to 2030) signal sustained revenue but with $0 outlay across most, indicating delayed realizations. Neutral Stanford NASA award ($131M) provides R&D stability; overall, prioritize construction exposure amid DHS infrastructure surge.

6 total filings
Β· daily

General Federal Contracts β€” March 11, 2026

DHS dominates with $1.34B (82%) of $1.63B total obligations, primarily in firm-fixed-price construction for border barriers, walls, Coast Guard piers, and ICE detention facilities, signaling accelerated border security infrastructure spend starting 2026. Five bullish signals highlight revenue visibility for construction firms (NAICS 236220), though $0 outlay across most flags funding delays. Isolated bullish IT cloud services ($160M) and neutral NASA R&D ($131M) provide sector diversification amid DHS concentration.

6 total filings
Β· daily

S&P 500 Consumer Staples Sector SEC Filings β€” March 11, 2026

Across 50 filings in the USA S&P 500 Consumer Staples intelligence stream (with broader cross-sector context), sentiment is predominantly mixed (24/50 filings), reflecting resilient revenue growth in staples outliers like Costco (+9.3% YoY Q2 revenue to $69.6B) amid declines in core players like Campbell's (-5% YoY Q2 net sales to $2.6B, lowered FY2026 guidance). Portfolio-level trends show 12/28 quantifiable revenue reporters with YoY growth averaging +24% (e.g., Oracle +22%, Marvell +42%), but 10 with declines averaging -12% (e.g., Nuwellis -5.4%, Campbell's -4.5% six-month); margins compressed in 8/15 (avg -150bps, e.g., Travelzoo 80.3% vs 87.5%), offset by expansions in 5 (e.g., Marvell +970bps to 51%). Capital allocation leans shareholder-friendly with dividends (ICL $232M, 3.1% yield; Pangaea $0.05/share) and buybacks (Campbell's $172M remaining; Core Molding +$6.5M to $7.5M total), while M&A/divestitures active (Elutia $88M BioEnvelope sale; Katapult pending merger). Forward-looking data flags lowered guidance (Campbell's organic sales -2% to flat) but optimistic catalysts (Netskope FY2027 revenue $870-876M; Elutia FDA 2H26). Proxy-heavy filings (12/50) signal governance focus ahead of April AGMs, with no major insider selling patterns but positive buyback conviction. Implications: Staples face volume headwinds/storm impacts, favor growth outliers like Costco; monitor margin trends and Q1 2026 catalysts for portfolio rotation.

26 high priority 24 medium 50 total filings
Β· daily

S&P 500 Industrials Sector SEC Filings β€” March 11, 2026

Across 50 SEC filings from S&P 500 Industrials and related entities dated March 11, 2026, the sector exhibits mixed FY2025 performance with 14/24 reporting companies showing revenue growth averaging +28% YoY (e.g., Serve Robotics +46%, Guardian Pharmacy +18%), but EBITDA declines in 7/15 cases averaging -35% (e.g., Target Hospitality -73%, Kewaunee flat amid backlog -17%). SPAC activity is volatile with 3 terminations/advances (Yotta negative, FG Merger II positive, GalaxyEdge IPO $100M), while M&A catalysts proliferate (Baker Hughes $9.5B notes for Chart, UWM pursuing Two Harbors). Guidance is constructive in 6 firms (Serve $26M 2026 rev up from prior, Guardian $120-124M EBITDA), but impairments and losses dominate (TechTarget $931M goodwill hit). Capital allocation leans defensive with dividends maintained (Heritage $0.13, UWM $0.10 quarterly), buybacks (Alpha Pro 685k shares), and low debt (Target Hosp zero net debt). Portfolio trends signal transportation/machinery resilience (Ryder EPS +8.4% YoY, TSR 146%) vs. construction/services weakness, with upcoming proxies/earnings as key catalysts.

29 high priority 21 medium 50 total filings
Β· daily

S&P 500 Energy Sector SEC Filings β€” March 11, 2026

Across the 8 S&P 500 Energy stream filings (with contextual financials), dominant themes include accelerating M&A momentum in energy services and E&P (Baker Hughes' $6.5B+€3B notes for Chart acquisition closing March 11, 2026; Devon's Coterra merger org structure), offset by geopolitical disruptions at SLB impacting Q1 EPS by $0.06-0.09. Period-over-period trends show robust growth at Peapack Gladstone (net income +13.1% YoY to $37.3M, NII +34.8% to $200.9M, loans +13.4% to $6.25B), but rising provisions (+213% to $23.5M) and capital ratio decline (-2.16 pts to 12.68%). Proxy season ramps up with neutral sentiment for IBKR, SHW annual meetings in April 2026, featuring director elections and comp votes. Positive sentiments dominate M&A filings (BKR, DVN at 9/10 and 8/10 materiality), while SLB and PGC are mixed due to ops headwinds and expense pressures. Portfolio-level patterns signal consolidation opportunities amid geo risks, with no insider trading noted but strong capital raises indicating conviction. Implications: Bullish for M&A plays, cautious on international exposure; watch deal closures and Q1 guidance.

5 high priority 3 medium 8 total filings
Β· daily

S&P 500 Financials Sector SEC Filings β€” March 11, 2026

Across 50 filings from S&P 500 Financials and adjacent sectors on March 11, 2026, dominant themes include heavy SPAC activity (12+ filings: IPOs, mergers, terminations, low redemptions), robust M&A (Cintas-UniFirst $5.5B, Contango-Dolly Varden), and mixed financial results with revenue growth outliers (AeroVironment +143% YoY Q3, TSS +66% FY, Acacia +133% FY) offset by declines (C3.ai -46% YoY Q3, Target Hospitality -17% FY). Period-over-period trends show average revenue growth ~20% YoY in high-performers but margin compression in 8/15 reporting companies (avg -150bps, e.g., Pangaea flat EBITDA margin, Smith Douglas -440bps gross margin), alongside capex surges (Oracle +$39.2B nine-months) and buyback/dividend commitments (News Corp $1B, ICL 3.1% yield). Capital allocation leans shareholder-friendly with buybacks/repurchases in 6 firms and dividends in 4, but SPAC redemptions average 6-92% signal dilution risks. Forward-looking data flags guidance cuts (Campbell's organic sales -2% to flat FY2026) and raises (TSS EBITDA $20-22M 2026), with catalysts like Contango special meeting March 17 and Cintas earnings March 25. Portfolio-level, financial services/SPACs show merger momentum but termination risks (Yotta), implying tactical opportunities in low-redemption de-SPACs (TLGY 6.7%) vs. avoid high-dilution IPOs (Pono 30% founder ownership). Overall, bullish M&A/deal flow contrasts deteriorating margins in growth names, favoring selective longs on guidance-backed outperformers.

25 high priority 25 medium 50 total filings
Β· daily

US Material Events SEC 8-K Filings β€” March 11, 2026

Across 50 filings dated March 11, 2026, dominant themes include robust M&A activity (e.g., Cintas-Unifirst $5.5B, Sonida $1.8B, Sphere 3D-Cathedra all-stock merger), extensive debt/equity financings ($3.5B Consolidated Edison revolver, $9.5B Baker Hughes notes for Chart acquisition, $1B Global Payments notes), and high executive churn (17+ resignations/appointments across firms like ON Semiconductor, Biogen, Axon). Limited period-over-period data shows positive revenue trends (Cintas Q3 FY2026 +8.9% YoY to $2.84B, organic +8.2%; no widespread declines), but dilution risks from convertible notes (CERO $937.5k face, SunPower $10M debenture) and SPAC setbacks (Yotta merger termination). Capital allocation leans toward growth via acquisitions/synergies ($375M Cintas, 62% FFO accretion Sonida) over buybacks/dividends. Sector patterns highlight services/hospitality consolidation, bitcoin infrastructure M&A, and neutral-to-positive sentiment in 70% of filings. Implications: Bullish for acquirers like Cintas/Sonida on synergies/accretion; monitor dilution in small caps and SPAC extensions amid tight liquidity.

50 high priority 50 total filings
Β· daily

S&P 500 Technology Sector SEC Filings β€” March 11, 2026

Across 15 SEC filings from the S&P 500 Technology stream (including software, semiconductors, IT services), dominant themes include robust revenue growth in cloud segments (Oracle Q3 +22% YoY to $17.2B, Cloud +44% to $8.9B), positive shareholder approvals at multiple AGMs (Maximus 93.2% quorum, Comtech all proposals passed), and proactive capital allocation via buybacks (Palo Alto +$1B authorization) and dividend hikes (Smurfit Westrock +5% to $0.4523/share, Oracle nine-mo $1.50 vs $1.20). Period-over-period trends show net income surges (Community West +398% YoY to $38.2M, Oracle nine-mo +42% to $12.8B) but offset by rising capex/debt (Oracle $39.2B capex, $134.6B debt) and compliance risks (GameSquare 2nd Nasdaq extension to Sep 7, 2026). Portfolio-level patterns reveal 4/4 detailed financials with YoY revenue/NI growth averaging +100%+, mixed sentiment (6/15 mixed/neutral), and clustered AGMs in April-May 2026 as catalysts. Critical implications: Tech growth intact but capex-heavy; monitor delisting risks and proxy votes for governance signals. Overall, bullish on capital returns amid growth, cautious on leverage/compliance outliers.

9 high priority 6 medium 15 total filings
Β· daily

Nasdaq 100 Stocks SEC Filings β€” March 11, 2026

Across 12 NASDAQ-100 related SEC filings from March 11, 2026, dominant themes include strong 2025 financial performance in packaging and retail (Smurfit Westrock $31.2B sales + synergies exceeded, Costco Q2 revenue +9.3% YoY to $69.6B, net income +13.8%), positive shareholder approvals at AGMs (Maximus 93.2% quorum, Comtech all proposals passed), and proactive capital management via dividend hikes (Smurfit +5% to $0.4523/share) and debt refinancings (Warner Music $1.295B term loan). Banking names show recovery with Community West net income +398% YoY to $38.2M and First Community strong KPI attainment (core ROAA 1.60% vs 1.11% target), but mixed with rising nonaccruals and declining investment yields. Period-over-period trends highlight revenue/earnings growth averaging +10-15% YoY in outperformers like Costco vs sector pressures, with no insider selling noted but limited activity reported. Portfolio-level implications favor consumer staples/retail momentum, while proxy battles and adjourned meetings signal governance watchpoints. Forward catalysts cluster around May AGMs and April reorganizations, positioning for post-vote repricings.

8 high priority 4 medium 12 total filings
Β· daily

Dow Jones 30 Stocks SEC Filings β€” March 11, 2026

Across 50 SEC filings from the USA Dow Jones 30 intelligence stream (though spanning broader US blue-chips and growth names), overarching themes include robust revenue acceleration in tech/hardware (e.g., AeroVironment +143% YoY Q3, Marvell +42% FY2026) offset by widening net losses from impairments/acquisitions (9/15 quantified firms showed losses expanding >100% YoY). Proxy statements dominate (20+ filings) signaling Q2 AGM season with strong board approvals and capital returns (PNC $3.9B to shareholders). M&A activity shines (Sonida $1.8B merger +62% FFO accretion, UWM pursuing Two Harbors), while biotech/healthcare mixed on trials/cuts (Vistagen 20% workforce reduction). Capital allocation tilts to buybacks/dividends (Levi $363M returned +26% YoY, Life Time $500M repurchase), but delisting risks (GameSquare) and going concern doubts (Evofem) flag vulnerabilities. Portfolio-level: Revenue grew avg +30% YoY in 12/20 trendable firms, margins mixed (5 expanded >500bps, 7 compressed), with positive FCF emerging (Netskope +$12.4M FY). Critical implications: Favor growth acquirers amid volatility, monitor Q2 catalysts.

28 high priority 22 medium 50 total filings
Β· daily

US SEC Filings Daily Market Digest β€” March 11, 2026

Across 50 SEC filings from March 11, 2026, key themes include robust M&A and SPAC activity with approvals for TLGY/StablecoinX and Contango/Dolly Varden, contrasted by terminations like Yotta/DRIVEiT; mixed financial results with standout growth in Oracle (Q3 rev +22% YoY, Cloud +44%), TSS (FY rev +66% YoY), and Acacia (FY rev +133% YoY), but sharp declines in C3.ai (Q3 rev -46% YoY) and Target Hospitality (FY rev -17% YoY). Margin pressures persist in housing (Smith Douglas -440 bps FY gross margin) and logistics (Pangaea FY NI -33% despite Q4 rev +25%), while capital allocation favors buybacks (News Corp $1B program) and dividends (ICL 3.1% yield, JNJ +5% quarterly). SPAC ecosystem shows momentum with IPO filings (BEST SPAC II $100M, Pono $150M) and merger votes, but delisting risks (GameSquare) and dilutions loom. Cloud/AI sectors outperform with guidance raises (TSS 2026 EBITDA $20-22M, Serve Robotics rev $26M), signaling portfolio rotation opportunities amid sector dispersion. Overall, bullish signals in tech/logistics outweigh bearish earnings misses, with catalysts clustered in Q2 2026 AGMs and trials.

28 high priority 22 medium 50 total filings
Β· daily

S&P 500 Consumer Discretionary Sector SEC Filings β€” March 11, 2026

Across 50 filings in the S&P 500 Consumer Discretionary stream (broadly including retail, services, and adjacent sectors), performance is mixed with robust growth in fintech/services (e.g., OppFi +17% YoY revenue, Wealthfront +18%) contrasting retail weakness (Target -1.7% sales YoY, -2.6% comps). Margin compression is evident in 7/15 quantified firms (avg -150bps, e.g., Oil-Dri -210bps, Target -30bps), driven by higher costs and disruptions, while 5 firms show expansion (e.g., Marvell +770bps to 51%). Major M&A theme emerges with UniFirst/Cintas $5.5B deal (multiple 425s, close H2 2026) and Boxabl/FG Merger advances; capital returns strong via buybacks (Life Time $500M, Wealthfront $100M) and dividends (Smurfit +5%, Oil-Dri +24%). SPAC activity neutral (Pono IPO $150M, LaFayette targets $500M-$1.5B), but biotech/health outliers like Evofem flag going concern risks. Forward catalysts cluster in Apr-May 2026 AGMs; overall, selective opportunities in growth/services amid retail caution.

32 high priority 18 medium 50 total filings
Β· daily

S&P 500 Healthcare Sector SEC Filings β€” March 11, 2026

Across 50 filings in the USA S&P 500 Healthcare intelligence stream (including contextual non-sector filings), healthcare firms exhibit mixed sentiment with biotechs like Minerva Neurosciences, Sagimet Biosciences, and Evofem Biosciences reporting widened net losses (e.g., Minerva -293.4M vs +1.4M prior) but advancing pipelines (Phase 3 initiations Q2 2026), while established players like Johnson & Johnson highlight exceptional 2025 growth in Oncology/Immunology and orthopaedics separation. Period-over-period trends show revenue growth in 12/50 (avg +25% YoY where reported, e.g., Acacia +133%, PNC +7%), but margin compression in 8/50 (avg -150bps, e.g., CID Holdco -3840bps) and net income declines in 10/50 (avg -60%, e.g., Montauk -82%). Capital allocation favors returns (PNC $3.9B dividends/buybacks), with M&A active (Cintas/UniFirst $5.5B EV at 8x EBITDA, accretive). Insider activity limited but neutral (WSFS CEO 10b5-1 sell plan). Key themes: Biotech cash infusions offset losses, cyber risks (Stryker), and AGMs as catalysts; portfolio implication - favor stable healthcare giants over high-burn biotechs amid 2026 trial readouts.

29 high priority 21 medium 50 total filings
Β· daily

Global High-Priority Regulatory Events β€” March 11, 2026

Across 50 filings in the 'Global High Priority Market Events' stream, dominant themes include intense SPAC activity (mergers, IPOs, terminations), major M&A completions/announcements (Cintas-UniFirst $5.5B, Sonida-CNHL $1.8B), mixed financial results with outliers like AeroVironment's 143% YoY revenue surge and C3.ai's 46% YoY plunge, positive insolvency resolutions in India, and minor regulatory fines. Period-over-period trends show revenue growth averaging +20% YoY in high-performers (e.g., Oracle +22%, ICL operating income +47%) but sharp declines in others (-4-46% YoY), with net losses widening in 6/10 detailed reports due to impairments/expenses; capital allocation favors dividends (ICL 3.1% yield, Smurfit +5%) over buybacks. Critical developments like SPAC approvals (TLGY 97% vote) and deal accretions signal bullish consolidation, while Nasdaq delisting risks (GameSquare) and guidance-absent distress (Fenoplast 95% dilution) pose threats. Portfolio-level patterns highlight SPAC resilience amid redemptions (avg 6-100%), Indian regulatory resolutions boosting stability, and tech/hardware growth vs. software weakness, implying opportunities in M&A plays and risks in high-debt growers like Oracle ($134B debt).

50 high priority 50 total filings
Β· daily

US IPO Pipeline SEC S-1 Filings β€” March 11, 2026

The IPO pipeline shows robust activity with 4 S-1 filings on March 11, 2026, including a new SPAC targeting consumer goods (BEST SPAC II), mining prep (Bunker Hill), a $200M debt follow-on (OFG Bancorp), and a high-risk dev-stage eCommerce play (OXO), with first 2 newly published signaling fresh momentum. Period data reveals stark contrasts: OXO's inception-period net loss of $4,701 and cash at $400 highlight early-stage vulnerabilities, while Bunker Hill's asset acquisitions (e.g., Pend Oreille Mill Aug 2024) and serial financings indicate operational ramp-up absent YoY metrics. BEST SPAC II's cheap founder shares ($0.0079/share) and sponsor commitment reflect strong skin-in-the-game, contrasting OXO's going concern doubts. Neutral/mixed sentiments dominate (3/4), but positive SPAC vibe suggests deSPAC catalysts ahead; portfolio trend of debt-heavy structures (Bunker loans, OFG notes, SPAC redemptions up to 15%) flags leverage risks amid no revenue growth visibility across filings. Market implications: Watch SPAC IPO execution for consumer sector entry, but avoid dev-stage traps without traction.

4 high priority 4 total filings
Β· daily

US Earnings Financial Results SEC Filings β€” March 11, 2026

Across the 50 filings in the Financial Results & Earnings stream (46 new), results are predominantly mixed with 22 positive, 15 negative, and 13 neutral sentiments, reflecting resilient growth in cloud/tech (e.g., Oracle +22% YoY revenue to $17.2B, Marvell +42% to $8.2B) and retail giants (Costco +9.3% Q2 revenue to $69.6B) offset by sharp declines in AI/software (C3.ai -46% Q3 revenue to $53.3M) and consumer staples (Campbell's -4.5%, Target -1.7% FY sales). Period-over-period trends show average revenue growth of +15% YoY in top performers (n=18) but -10% in laggards (n=12), with margin compression averaging -100bps in 14 companies due to higher OpEx/R&D; banks expanded assets +30% avg (n=5) but NIM mixed (improving in CNB/LCNB, declining elsewhere). Biotechs/pharmas (n=12) narrowed net losses 20-77% via cost cuts, while SPACs (n=4) saw trust redemptions -70-92%. Capital allocation favors dividends/buybacks in stables (Costco EPS +14%, Oil-Dri dividends +24%), acquisitions drive growth (AeroVironment +143% revenue). Portfolio implications: overweight tech/cloud/defense outperformers, underweight high-burn AI/biotechs; watch bank NIM and biotech cash burns for Q1 2026 catalysts amid 2026-03 period focus.

50 high priority 50 total filings
Β· daily

US Executive Compensation Proxy SEC Filings β€” March 11, 2026

Across 30 DEF 14A proxy statements, 2025 financial performance was predominantly strong with 18/30 filings highlighting YoY revenue growth averaging ~7% (e.g., PNC +7%, Levi +7% organic, Genpact +6.6%, Graco +6%), EPS expansion (Ryder +8.4%, Northern Trust +17%, C&F +38%), and robust capital returns including $3.9B shareholder payouts at PNC and $2.4B buybacks at MSCI. Positive sentiment dominates (14/30 filings), driven by innovation, M&A (PNC's FirstBank adding $26B assets post-2025), and expansions (Life Time's 10 new clubs, JNJ's Orthopaedics separation), while mixed/neutral tones appear in flat revenue cases like Valmont (~$4.1B unchanged YoY) and incentive declines (Triumph non-equity -2% YoY). Portfolio-level trends show financials leading with avg net income +20% YoY (PNC +18%, C&F +36%), industrials mixed (Graco sales +6% but TSR flat), and high insider alignment via equity-heavy comp (Triumph CEO stock awards $2.81M driving +31% total pay). Forward-looking catalysts cluster in April-May 2026 AGMs for comp votes (say-on-pay >90% historical approvals like AMETEK 95% avg), auditor ratifications, and director elections amid board refreshes (JNJ adding Pinto/Morikis, Levi chair transition). Capital allocation favors dividends (+5-8% at Smurfit/Graco) and buybacks (Life Time $500M new program), signaling confidence; however, controlled companies (Biglari, Travelzoo) exempt from some governance norms raise minor flags. Overall, bullish for growth names pre-AGM, with watch for say-on-pay risks in mixed comp filers.

30 high priority 30 total filings
Β· daily

US Executive Officer Management Changes SEC β€” March 11, 2026

Across 36 filings in the USA Executive & Director Changes stream (March 11, 2026), executive turnover dominates with 18 departures/resignations (e.g., CFOs at Lattice, Bridger, Peloton; Group Presidents at onsemi; CLO at Biogen), mostly neutral sentiment and not due to disagreements, signaling routine transitions amid sector shifts. Positive appointments (9 cases, e.g., experienced CFOs at Navitas/Bridger, Chairman at Mainz Biomed pivoting to Quantum Cyber) outnumber negatives, with compensation enhancements (e.g., PSUs extensions at Target Hospitality, salary hikes at Farmer Mac) in 7 filings indicating retention focus. Limited period-over-period financials show outliers like Tilly's Q4 FY2025 sales +5.3% YoY (comp sales +10.1%) vs FY -2.8%, Atlassian's cloud revenue +25% despite 10% layoffs, and Blue Bird's equity plan expansion +17.3% shares. No widespread insider trading but high CFO churn (5 cases) raises conviction questions; forward-looking catalysts cluster in Q2 2026 (EGMs, annual meetings). Portfolio-level: Neutral-to-positive board refreshments in semis/AI/crypto, potential alpha from undervalued turnarounds but risks from undisclosed details in 5 filings. Overall, low materiality average (5.5/10) suggests limited immediate volatility but monitor transitions for operational hiccups.

36 high priority 36 total filings